Concepedia

Massimo Broggini

MB

Statistics

Publications

160

Citations

8K

H-Index

52

Active since

1977

Affiliations

Mario Negri Institute for Pharmacological Research(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

University of Milan

Fondazione IRCCS Istituto Nazionale dei Tumori

Massimo Broggini is an author at Mario Negri Institute for Pharmacological Research specializing in medicine, oncology, and molecular oncology.

Publications per year

1977–2025

160

Publications

160

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 477 citations

Medicine, Oncology, Pharmacology +14

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743

Mario Minuzzo, Sergio Marchini, Massimo Broggini et al. · Proceedings of the National Academy of Sciences · 2000 · 195 citations · Full text

Medicine, Molecular Biology, Pharmacology +15

Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy

Tullio Bertani, F Cutillo, Carla Zoja et al. · Kidney International · 1986 · 182 citations · Full text

Medicine, Nephrology, Pathology +15

Oct‐4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker

Stefano Zangrossi, Mirko Marabese, Massimo Broggini et al. · Stem Cells · 2007 · 172 citations

Life Sciences, Cell Biology, Developmental Biology +16

p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.

Domizia Debernardis, Eva Graniela Siré, P. De Feudis et al. · PubMed · 1997 · 148 citations

Medicine, Oncology, Pharmacology +17

1–5 of 160